Call Number (LC) Title Results
HE 20.4702:B 13/2/DRAFT Guidance for industry acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease : developing antimicrobial drugs for treatment. 1
HE 20.4702:B 23 Guidance for industry bar code label requirements, questions and answers. 1
HE 20.4702:B 38 FDA lanza advertencia publica contra el uso de crema de belleza 1
HE 20.4702:B 46 Cuál es la mejor manera de tomar su medicina comprada sin receta médica? con seriedad. 1
HE 20.4702:B 52 Quality of biotechnological products analysis of the expression construct in cells used for production of r-DNA derived protein products. 1
HE 20.4702:B 52/2 Guidance for industry Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process. 1
HE 20.4702:B 52/3/DRAFT Guidance for industry bioequivalence recommendations for specific products. 1
HE 20.4702:B 52/4 Guidance for industry bioanalytical method validation. 1
HE 20.4702:B 52/5 Guidance for industry bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. 1
HE 20.4702:B 52/6 Guidance for industry statistical approaches to establishing bioequivalence. 1
HE 20.4702:B 52/7 Guidance for industry waiver of in vivo bioavailability studies for immediate-release soild oral dosage forms based on a biopharmaceutics classification system. 1
HE 20.4702:B 52/DRAFT Guidance for industry submission of summary bioequivalence data for ANDAs. 1
HE 20.4702:B 56 En busca de una mejoría para los problemas de la vejiga 1
HE 20.4702:B 65 Guidance for industry botanical drug products. 1
HE 20.4702:B 72 Guidance for industry Q1D bracketing and matrixing designs for stability testing of new drug substances and products. 1
HE 20.4702:B 74 Alimentando a su bebé con leche materna o biberón 1
HE 20.4702:B 78 Guidance for industry consumer-directed broadcast advertisements. 1
HE 20.4702:B 78/2 Guidance for industry consumer-directed broadcast advertisements, questions and answers. 1
HE 20.4702:C 17 Guidance for industry S1B testing for carcinogenicity of pharmaceuticals. 1
HE 20.4702:C 17/2 Guidance for industry carcinogenicity study protocol submissions. 1